Parametric Release and Real-Time Release Testing: A Practical Guide

For most sterile products, the last thing standing between a finished batch and the market is a 14-day sterility test. For terminally sterilized products, that test adds time but very little assurance. Parametric release replaces it with evidence from the sterilization process itself. Real-time release testing (RTRT) extends the same idea to other quality attributes, using process data instead of end-product tests. This guide explains what both mean, what FDA, EU and USP expect, and why adoption is still slower than the science would suggest.

What Parametric Release Is

FDA defines parametric release as a sterility assurance release program in which controlled critical process parameters replace the sterility test for batch release (FDA, 2010). EU GMP Annex 17 describes it the same way: release of terminally sterilized product based on a review of critical process control parameters rather than sterility testing (European Commission, 2018).

It only works where the process is well understood and its lethality can be calculated. USP <1222> notes that a sterility assurance level (SAL) can be calculated for terminal sterilization but only estimated for aseptic processing. The usual target is a probability of a non-sterile unit of not more than one in a million, or 10⁻⁶ (USP <1222>). That is why parametric release applies to terminally sterilized products, not aseptically filled ones.

Why the Sterility Test Falls Short

The compendial sterility test samples a small number of units from a batch that may contain tens of thousands. Both FDA and Annex 17 say the test is limited in its ability to detect contamination and will catch only major failures (FDA, 2010). USP <1222> calls it statistically ill-suited to terminally sterilized products.

The arithmetic is stark. With 20 units tested, a batch with 1% contaminated units has only an 18.1% chance of failing the test. At 0.1% contamination, the chance drops to 2.0% (Nelson Labs). A validated sterilization cycle, monitored every run, tells you far more about every unit in the load than a 20-unit sample ever can.

“A sterility test samples a batch. A validated sterilization cycle treats every unit in the load. Parametric release simply trusts the better evidence.”

Regulatory Frameworks

• FDA (2010). The final guidance sets out what NDA, ANDA, BLA and veterinary applicants should submit to support parametric release of products terminally sterilized by moist heat (FDA). Approval is needed before use.
• EU GMP Annex 17 (2018). The revised annex came into operation on 26 December 2018. The earlier version covered only parametric release; the revision added RTRT for finished products, active substances and intermediates (ECA Academy).
• USP <1222>. The informational chapter covers moist heat, dry heat, ethylene oxide and ionizing radiation. For radiation it describes dosimetric release, based on chemical dosimeters. It notes that parametric release is not widely used for ethylene oxide, because its parameters interact (USP <1222>).
• PAT and ICH Q13. FDA’s 2004 PAT framework defined real time release as the ability to evaluate and ensure quality based on process data (FDA, 2004). ICH Q13 on continuous manufacturing, adopted on 16 November 2022, builds RTRT and PAT into the control strategy (Pharmaceutical Online).

What Regulators Expect

The core requirements are consistent across FDA, EU and USP. Expect to show the following.

• A validated cycle. The terminal sterilization process must be validated, with a defined development approach: overkill (generally F₀ of at least 12 minutes), bioburden-based, or combined biological indicator and bioburden.
• Defined critical parameters. Applicants identify each critical process parameter with minimum and maximum limits. FDA treats the sterilization load monitor as a critical parameter in its own right.
• Load monitors. Physical, chemical or biological indicators with each load. FDA recommends Class 5 integrating indicators for most chemical indicator uses.
• Bioburden control. Annex 17 expects pre-sterilization bioburden testing on each batch, with isolates checked for spore formers. Bioburden-based cycles need spore detection and heat resistance studies.
• Independent record review. Annex 17 requires sterilization records to be checked by at least two independent systems, such as two people, or a validated computer system plus a person.
• Trained, experienced staff. Personnel need documented experience in microbiology, sterility assurance, engineering and sterilization.
• Strict deviation handling. If a critical parameter is not met, the load is rejected unless an approved reprocessing route exists.

RTRT and Continuous Manufacturing

RTRT applies the parametric idea beyond sterility. Instead of testing a finished tablet for assay or content uniformity, a manufacturer can use validated in-line measurements, such as near-infrared spectroscopy, combined with material attributes and process controls. Annex 17 sets minimum criteria: the RTRT strategy must be built into the pharmaceutical quality system, covering change control, the control strategy, training, validation, deviation handling and continuous learning. Attributes controlled by RTRT still appear on the certificate of analysis, footnoted as controlled by approved RTRT.

Continuous manufacturing is where RTRT makes the most sense. Material moves through the line without hold points, so waiting days for lab results defeats the purpose. ICH Q13 expects firms to understand residence time distribution and to divert non-conforming material during start-up or upsets (ICH Q13). PAT models and diversion logic then become part of the release decision. Like any alternative method, the analytical tools still need to be validated and shown to be at least equivalent to the methods they replace; our posts on compendial method verification and microbiology method suitability cover the foundations.

Barriers to Adoption

• Upfront investment. Validation studies, instrumentation, data systems and models cost money before any time is saved.
• Regulatory variation. Approval is needed in each market, and multi-market products must satisfy every authority’s expectations at once.
• Process limits. Ethylene oxide cycles and complex biologics are harder to control by parameters alone.
• Culture. QC teams used to final tests must trust data review and process understanding instead.
• Data integrity. Release now depends on sensors, software and records. Computerized system validation becomes critical.

What This Means for Sterile and Advanced Manufacturers

If you terminally sterilize by moist heat or radiation, parametric or dosimetric release is worth assessing now. The benefits are faster release, lower inventory, fewer sterility test investigations and a more honest picture of sterility assurance. Start with a gap assessment against FDA guidance and Annex 17: cycle validation approach, load monitors, bioburden data, record review and deviation rules. For oral solids on a continuous line, plan RTRT into the control strategy from development, not as a retrofit.

Engage regulators early, and build the submission around clear process understanding. Terraforme Biosciences helps manufacturers plan parametric release and RTRT strategies, prepare supporting documentation and manage regulatory interactions. Learn more about our regulatory guidance services.